Centalun

Centalun

Systematic (IUPAC) name
2-methyl-1-phenylbut-3-yne-1,2-diol
Clinical data
Legal status	Unscheduled
Identifiers
CAS Number	2033-94-5
ATC code	none
PubChem	CID 16252
ChemSpider	15421
Chemical data
Formula	C11H12O2
Molar mass	176.212 g/mol
SMILES OC(c1ccccc1)C(C#C)(O)C
InChI InChI=1S/C11H12O2/c1-3-11(2,13)10(12)9-7-5-4-6-8-9/h1,4-8,10,12-13H,2H3 Key:GQOXDWHRXDPZJK-UHFFFAOYSA-N
(what is this?)  (verify)

Centalun was developed by Boehringer Ingelheim in 1962^[1] and is a psycholeptic drug with hypnotic and sedative effects, via allosteric agonism of the GABA_A receptor.^[2] It was previously used for sedation in medical procedures such as surgery,^[3] orthopedics^[4] and gynecology,^[5] although it is no longer in clinical use. Despite its history of clinical use, centalun was never incorporated into the CSA and therefore remains unregulated as a drug of abuse.

References

1. BE Patent 618130
2. Janke, W.; Glathe, H. (1964). "Experimental Studies on the Psychic Effect of Sedatives Under Normal and Stress Conditions". Psychologische Forschung 27: 377–402. PMID 14233519.
3. Monecke, K. (1964). "Pre- and Postoperative Use of Centalun in Surgery". Deutsches medizinisches Journal 15: 470–471. PMID 14238754.
4. Bruckschen, E. (1964). "Sedative Therapy with Centalun in Orthopedics". Deutsches medizinisches Journal 15: 493–494. PMID 14243120.
5. Gerlach, W.; Gerlach, E. (1964). "Experiences with Centalun in Obstetrical and Gynecological Patients". Medizinische Monatsschrift 18: 131–133. PMID 14193290.